Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3727)	2/4/1998 1:50:00 AM
From: David S.	Read Replies (2) \| Respond to of 6136

"Then why was VRTX done". Can we try for complete thoughts, John? Then I will be able to respond to them, but I do not want to assume what you are trying to communicate. What is also interesting though, caught out of the corner of my eye as I was leaving the coal mine today, is that the notion of unique mutation profiles being so wonderful for a protease inhibitor that you may know of, and of course, ones in the pipeline from other companies - well, it may not be all that's it's been cracked up to be. I'll try to find the thing tomarrow, and give you the direct source, but right now I am home in my jammies so you'll just have to wait. How's the rain in Diego?

To: JOHN W. who wrote (3727)	2/4/1998 10:27:00 AM
From: Oliver & Co	Respond to of 6136

"AIDS Drugs Are Effective in Twice-Daily Regimen" Wall Street Journal (02/04/98) P. B13 ÿÿÿÿ At the Fifth Conference on Retroviruses and Opportunistic Infections, Agouron Pharmaceuticals and Merck & Co. announced that their protease inhibitors--Viracept and Crixivan, respectively--are as effective when taken twice daily as the thrice daily regimen used to reduce the level of HIV in patients' blood.ÿ The new data implies that patients taking the drug cocktails may be able to reduce the number of times per day they have to take the medicine.ÿ The complex regimen of taking several pills at varying times during the day has been one key reason why many patients on the multi-drug therapy fail.ÿ Agouron officials noted that the cost of the twice daily Viracept regimen would cost about $500 more per year, although the strength of the medicine in terms of milligrams remains the same.